us-fda-guidance-73ca77a9f8c9469282dc06a570c7d83e•Guidance for the Development of Vaginal Contraceptive Drugs (NDA)
Guidance for the Development of Vaginal Contraceptive Drugs (NDA)
us-fda-guidance-73ca77a9f8c9469282dc06a570c7d83eGuidance for the Development of Vaginal Contraceptive Drugs (NDA)Guidance
Administrative guidance, not enacted legislation. This captured publisher edition preserves the listed document and attachments; later developments are not independently consolidated.
The FDA published Good Guidance Practices in February 1997. This guidance was developed and issued prior to that date.
Submit Comments
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.
Setzen Sie Ihre Recherche in ChatGPT oder Claude fort
Verbinden Sie Omnilex, um den Rechtskorpus über Ihren KI-Assistenten zu durchsuchen.